J&J unit settles state Risperdal claims for $181M 
Published: September 5, 2012
Tags: anti-psychotic drugs, consumer protection, FDA, Food and Drug Administration, Johnson & Johnson, off-label uses, Risperdal
Johnson & Johnson has agreed to pay a record $181 million to settle claims brought by New York and 36 other states that the company’s Janssen Pharmaceuticals unit improperly marketed Risperdal and other anti-psychotic drugs for “off-label” uses.
Maker of Risperdal hit with $1.1 billion fraud verdict
Published: April 18, 2012
Tags: consumer protection, fraud, Medicaid, Medicaid fraud, Risperdal
The maker of the antipsychotic drug Risperdal has been ordered to pay $1.1 billion for defrauding Arkansas’ Medicaid program.
FDA issues warning on Risperdal, Requip confusion
Published: June 29, 2011
Tags: drug safety, FDA, Food and Drug Administration, medication errors, Requip, Risperdal
The Food and Drug Administration has issued a drug safety warning to the public about confusion between two similarly named and packaged drugs.
Judge orders maker of Risperdal to pay $327 million
Published: June 27, 2011
Tags: deceptive trade practices, drug marketing, Johnson & Johnson, Ortho-McNeil Pharmaceutical, Ortho-McNeil-Janssen Pharmaceutica, prescription drugs, Risperdal
A judge has ordered the maker of Risperdal to pay $327 million in civil penalties to the state of South Carolina for its marketing of the antipsychotic drug.
FDA warning letters don’t establish consumer fraud
By:
Pat Murphy
Published: December 6, 2010
Tags: consumer fraud, Duragesic, false advertising, FDA, product liability, Risperdal
Warning letters issued by the U.S. Food and Drug Administration do not conclusively establish that a drug manufacturer misled consumers about the risks of taking its products, West Virginia’s highest court has ruled in reversing a $4.5 million penalty.
J&J must pay $257M over Risperdal marketing
By:
Pat Murphy
Published: October 15, 2010
Tags: product liability, Risperdal
Johnson & Johnson lost a $257.7 million jury verdict in Louisiana for making misleading claims about the safety of the company’s Risperdal antipsychotic drug.
Utah sues drugmakers for off-label marketing
By:
Nora Tooher
Published: May 11, 2010
Tags: AstraZeneca, bipolar disorder, FDA, Food and Drug Administration, Johnson & Johnson, off-label marketing, Risperdal, schizophrenia, Seroquel
Utah’s attorney general has filed suit against Johnson & Johnson and AstraZeneca for allegedly illegal off-label marketing of anti-psychotic drugs.
J&J pushed Risperdal after warning, files show
By:
Pat Murphy
Published: March 10, 2010
Tags: Risperdal
The U.S. Attorney’s office in Boston announced that the Justice Department has filed a False Claims Act complaint against Johnson & Johnson and two subsidiaries for allegedly paying millions of dollars in kickbacks to nursing homes to prescribe its anti-psychotic drug Risperdal.
Justice Dept. joins Risperdal whistleblower suits
By:
Nora Tooher
Published: January 19, 2010
Tags: black box warning, Department of Justice, False Claims Act, nursing home, Risperdal, whistleblower
The U.S. Attorney’s office in Boston announced that the Justice Department has filed a False Claims Act complaint against Johnson & Johnson and two subsidiaries for allegedly paying millions of dollars in kickbacks to nursing homes to prescribe its anti-psychotic drug Risperdal.
